Towards precision therapy in HER2-positive early-stage breast cancer.

COI Statement

Declaration of competing interest The authors declare the following financial interests/personal relationships that may be considered potential competing interests: Serena Di Cosimo reported receiving an institutional grant (IG 20774) from the Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC); funding from the Cancer Can.Heal European EU4Health Programme (101080009 - European Commission); serving as an “ad hoc” medical monitor for Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain); as well as support for attending meetings and/or travel from Daiichi Sankyo, and participation in an advisory board for Pfizer. Paolo Verderio and Serena Di Cosimo are leading the PNRR-POC-2023-12378113 project, founded by the European Union - Next Generation EU – PNRR M6C2 – Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedical del SSN, titled “A Composite Assay for HER2-Positive Early-Stage Breast Cancer Management”.